Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-Apr-24 4:02 PM View:  | Ambrose Kristen SVP & Chief Accounting Officer | Vertex Pharmaceuticals Inc. (VRTX) | 02-Apr-24 | Sale (Planned) | 240 | $419.00 | $100,560.00 | (3%) 7.74K to 7.5K | |
| 03-Apr-24 4:02 PM View: | Ambrose Kristen SVP & Chief Accounting Officer | Vertex Pharmaceuticals Inc. (VRTX) | 01-Apr-24 | Payment of Exercise | 225 | $418.10 | $94,072.50 | (3%) 7.96K to 7.74K | |
| 27-Feb-24 4:44 PM View: | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 883 | $425.70 | $375,893.00 | (5%) 16.86K to 15.97K | |
| 27-Feb-24 5:02 PM View: | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 354 | $425.70 | $150,698.00 | (< 1%) 56.16K to 55.8K | |
| 27-Feb-24 4:37 PM View: | Arbuckle Stuart A EVP, COO | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 5,034 | $425.70 | $2,142,970.00 | (9%) 54.87K to 49.83K | |
| 27-Feb-24 4:59 PM View: | Sachdev Amit EVP Chief Patient & Ext Af Off | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 3,004 | $425.70 | $1,278,800.00 | (5%) 65.78K to 62.77K | |
| 27-Feb-24 4:24 PM View: | Altshuler David EVP, Global Research and CSO | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 4,239 | $425.70 | $1,804,540.00 | (14%) 30.05K to 25.81K | |
| 27-Feb-24 4:29 PM View: | Ambrose Kristen SVP & Chief Accounting Officer | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 883 | $425.70 | $375,893.00 | (10%) 8.85K to 7.96K | |
| 27-Feb-24 4:29 PM View: | Ambrose Kristen SVP & Chief Accounting Officer | Vertex Pharmaceuticals Inc. (VRTX) | 23-Feb-24 | Payment of Exercise | 828 | $431.79 | $357,522.00 | (9%) 9.68K to 8.85K | |
| 27-Feb-24 4:24 PM View: | Altshuler David EVP, Global Research and CSO | Vertex Pharmaceuticals Inc. (VRTX) | 23-Feb-24 | Payment of Exercise | 3,970 | $431.79 | $1,714,210.00 | (12%) 34.02K to 30.05K | |
| 27-Feb-24 4:55 PM View: | Kewalramani Reshma CEO & President Director | Vertex Pharmaceuticals Inc. (VRTX) | 23-Feb-24 | Payment of Exercise | 9,386 | $431.79 | $4,052,780.00 | (6%) 145.89K to 136.51K | |
| 27-Feb-24 5:08 PM View: | Wagner Charles F Jr EVP & Chief Financial Officer | Vertex Pharmaceuticals Inc. (VRTX) | 23-Feb-24 | Payment of Exercise | 3,309 | $431.79 | $1,428,790.00 | (6%) 56.89K to 53.58K | |
| 27-Feb-24 4:44 PM View: | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Vertex Pharmaceuticals Inc. (VRTX) | 23-Feb-24 | Payment of Exercise | 1,654 | $431.79 | $714,181.00 | (9%) 18.51K to 16.86K | |
| 27-Feb-24 5:02 PM View: | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Vertex Pharmaceuticals Inc. (VRTX) | 23-Feb-24 | Payment of Exercise | 3,309 | $431.79 | $1,428,790.00 | (6%) 59.47K to 56.16K | |
| 27-Feb-24 4:50 PM View: | Bozic Carmen EVP and CMO | Vertex Pharmaceuticals Inc. (VRTX) | 23-Feb-24 | Payment of Exercise | 3,309 | $431.79 | $1,428,790.00 | (8%) 40.25K to 36.94K | |
| 27-Feb-24 4:37 PM View: | Arbuckle Stuart A EVP, COO | Vertex Pharmaceuticals Inc. (VRTX) | 23-Feb-24 | Payment of Exercise | 4,714 | $431.79 | $2,035,460.00 | (8%) 59.58K to 54.87K | |
| 27-Feb-24 4:59 PM View: | Sachdev Amit EVP Chief Patient & Ext Af Off | Vertex Pharmaceuticals Inc. (VRTX) | 23-Feb-24 | Payment of Exercise | 2,469 | $431.79 | $1,066,090.00 | (4%) 68.25K to 65.78K | |
| 23-Feb-24 4:12 PM View: | Arbuckle Stuart A EVP, COO | Vertex Pharmaceuticals Inc. (VRTX) | 21-Feb-24 | Private Sale (Planned) | 3,603 | $421.77 | $1,519,640.00 | (6%) 63.18K to 59.58K | |
| 23-Feb-24 4:20 PM View: | Sachdev Amit EVP Chief Patient & Ext Af Off | Vertex Pharmaceuticals Inc. (VRTX) | 21-Feb-24 | Private Sale (Planned) | 3,191 | $421.77 | $1,345,870.00 | (4%) 71.44K to 68.25K | |
| 23-Feb-24 4:10 PM View: | Altshuler David EVP, Global Research and CSO | Vertex Pharmaceuticals Inc. (VRTX) | 21-Feb-24 | Private Sale (Planned) | 3,002 | $421.77 | $1,266,150.00 | (8%) 37.02K to 34.02K | |
| 23-Feb-24 4:16 PM View: | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Vertex Pharmaceuticals Inc. (VRTX) | 21-Feb-24 | Private Sale (Planned) | 1,201 | $421.77 | $506,546.00 | (6%) 19.71K to 18.51K | |
| 23-Feb-24 4:28 PM View: | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Vertex Pharmaceuticals Inc. (VRTX) | 21-Feb-24 | Private Sale (Planned) | 360 | $421.77 | $151,837.00 | (< 1%) 59.83K to 59.47K | |
| 21-Feb-24 4:29 PM View: | Kewalramani Reshma CEO & President Director | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Payment of Exercise | 7,019 | $420.58 | $2,952,050.00 | (5%) 152.91K to 145.89K | |
| 21-Feb-24 4:49 PM View: | Wagner Charles F Jr EVP & Chief Financial Officer | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Payment of Exercise | 2,812 | $420.58 | $1,182,670.00 | (5%) 59.7K to 56.89K | |
| 21-Feb-24 4:23 PM View: | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Payment of Exercise | 1,125 | $420.58 | $473,152.00 | (5%) 21.64K to 20.51K | |
| 21-Feb-24 4:23 PM View: | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Sale (Planned) | 801 | $420.79 | $337,053.00 | (4%) 20.51K to 19.71K | |
| 21-Feb-24 4:43 PM View: | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Payment of Exercise | 3,373 | $420.58 | $1,418,620.00 | (5%) 63.68K to 60.31K | |
| 21-Feb-24 4:43 PM View: | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Sale (Planned) | 480 | $420.79 | $201,979.00 | (< 1%) 60.31K to 59.83K | |
| 21-Feb-24 4:34 PM View: | Leiden Jeffrey M Executive Chairman Director | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Payment of Exercise | 4,118 | $420.58 | $1,731,950.00 | (22%) 18.34K to 14.22K | |
| 21-Feb-24 4:26 PM View: | Bozic Carmen EVP and CMO | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Payment of Exercise | 2,812 | $420.58 | $1,182,670.00 | (7%) 43.06K to 40.25K | |
| 21-Feb-24 4:19 PM View: | Arbuckle Stuart A EVP, COO | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Payment of Exercise | 3,373 | $420.58 | $1,418,620.00 | (5%) 71.36K to 67.99K | |
| 21-Feb-24 4:38 PM View: | Sachdev Amit EVP Chief Patient & Ext Af Off | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Payment of Exercise | 2,623 | $420.58 | $1,103,180.00 | (3%) 78.31K to 75.69K | |
| 21-Feb-24 4:19 PM View: | Arbuckle Stuart A EVP, COO | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Sale (Planned) | 4,804 | $420.79 | $2,021,480.00 | (7%) 67.99K to 63.18K | |
| 21-Feb-24 4:38 PM View: | Sachdev Amit EVP Chief Patient & Ext Af Off | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Sale (Planned) | 4,254 | $420.79 | $1,790,040.00 | (6%) 75.69K to 71.44K | |
| 21-Feb-24 4:13 PM View: | Altshuler David EVP, Global Research and CSO | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Payment of Exercise | 2,812 | $420.58 | $1,182,670.00 | (6%) 43.84K to 41.03K | |
| 21-Feb-24 4:13 PM View: | Altshuler David EVP, Global Research and CSO | Vertex Pharmaceuticals Inc. (VRTX) | 20-Feb-24 | Sale (Planned) | 4,002 | $420.79 | $1,684,000.00 | (10%) 41.03K to 37.02K | |
| 21-Feb-24 4:49 PM View: | Wagner Charles F Jr EVP & Chief Financial Officer | Vertex Pharmaceuticals Inc. (VRTX) | 16-Feb-24 | Payment of Exercise | 3,750 | $424.01 | $1,590,040.00 | (6%) 63.45K to 59.7K | |
| 21-Feb-24 4:23 PM View: | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Vertex Pharmaceuticals Inc. (VRTX) | 16-Feb-24 | Payment of Exercise | 1,501 | $424.01 | $636,439.00 | (6%) 23.14K to 21.64K | |
| 21-Feb-24 4:43 PM View: | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Vertex Pharmaceuticals Inc. (VRTX) | 16-Feb-24 | Payment of Exercise | 4,499 | $424.01 | $1,907,620.00 | (7%) 68.18K to 63.68K | |
| 21-Feb-24 4:26 PM View: | Bozic Carmen EVP and CMO | Vertex Pharmaceuticals Inc. (VRTX) | 16-Feb-24 | Payment of Exercise | 3,750 | $424.01 | $1,590,040.00 | (8%) 46.81K to 43.06K | |
| 21-Feb-24 4:19 PM View: | Arbuckle Stuart A EVP, COO | Vertex Pharmaceuticals Inc. (VRTX) | 16-Feb-24 | Payment of Exercise | 4,499 | $424.01 | $1,907,620.00 | (6%) 75.86K to 71.36K | |
| 21-Feb-24 4:38 PM View: | Sachdev Amit EVP Chief Patient & Ext Af Off | Vertex Pharmaceuticals Inc. (VRTX) | 16-Feb-24 | Payment of Exercise | 3,498 | $424.01 | $1,483,190.00 | (4%) 81.81K to 78.31K | |
| 21-Feb-24 4:13 PM View: | Altshuler David EVP, Global Research and CSO | Vertex Pharmaceuticals Inc. (VRTX) | 16-Feb-24 | Payment of Exercise | 3,750 | $424.01 | $1,590,040.00 | (8%) 47.59K to 43.84K | |
| 21-Feb-24 4:29 PM View: | Kewalramani Reshma CEO & President Director | Vertex Pharmaceuticals Inc. (VRTX) | 16-Feb-24 | Payment of Exercise | 9,359 | $424.01 | $3,968,310.00 | (6%) 162.27K to 152.91K | |
| 16-Feb-24 4:07 PM View: | Leiden Jeffrey M Executive Chairman Director | Vertex Pharmaceuticals Inc. (VRTX) | 15-Feb-24 | Sale (Planned) | 4,655 | $419.16 | $1,951,190.00 | (20%) 22.99K to 18.34K | |
| 16-Feb-24 4:07 PM View: | Leiden Jeffrey M Executive Chairman Director | Vertex Pharmaceuticals Inc. (VRTX) | 14-Feb-24 | Private Sale (Planned) | 4,356 | $419.04 | $1,825,340.00 | (16%) 27.35K to 22.99K | |
| 14-Feb-24 4:04 PM View: | Leiden Jeffrey M Executive Chairman Director | Vertex Pharmaceuticals Inc. (VRTX) | 13-Feb-24 | Sale (Planned) | 737 | $419.13 | $308,899.00 | (3%) 28.08K to 27.35K | |
| 13-Feb-24 4:54 PM View: | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Vertex Pharmaceuticals Inc. (VRTX) | 12-Feb-24 | Sale (Planned) | 913 | $420.24 | $383,679.00 | (4%) 24.05K to 23.14K | |
| 13-Feb-24 10:00 PM View: | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Vertex Pharmaceuticals Inc. (VRTX) | 12-Feb-24 | Sale (Planned) | 314 | $420.24 | $131,955.00 | (< 1%) 68.49K to 68.18K | |
| 13-Feb-24 4:51 PM View: | Arbuckle Stuart A EVP, COO | Vertex Pharmaceuticals Inc. (VRTX) | 12-Feb-24 | Sale (Planned) | 4,295 | $420.24 | $1,804,930.00 | (5%) 80.15K to 75.86K |
